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Issue
For the first time, the most common and most deadly form of cancer -cancer of the lung -can be detected early enough to save lives. Research over the past decade and the results of the National Lung Screening Trial (NLST) 2 support screening of high-risk patients with low dose spiral computed tomography (LDCT) to reduce lung cancer mortality.
However, the promise of LDCT screening in highrisk populations raises a host of complex practical, clinical, research, and policy issues.
• Berg CD, et al; National Lung Screening Trial Research Team. Reduced lung cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5): 395-409 .
Potential harms of screening
False positives/unnecessary follow up 24% of scans in NLST were abnormal; 39% of participants had at least one abnormal scan; of these abnormal scans 96% were determined nonmalignant.
Over-diagnosis
Screening tends to catch more indolent, less deadly malignancies and may subject many patients to overtreatment and subsequent harms.
Psychological distress
Anxiety from false positives, uncertainty, need for further workup, time away from work, and relationship stress represent harder-to-measure but undeniable burdens.
Exposure risks
The American College of Radiology estimates that if all high risk people had this screening, the radiation exposure could cause one additional fatal cancer for each thousand people tested.
Cost
Questionable coverage and incurred out of pocket costs add to the financial burden of screening. Pressure for broadened screening criteria in real-world settings may, in fact, yield more care and more costs without the corresponding benefits in terms of reduced mortality. cancer 3 as a basis for development of professional guidelines. The largest and most influential among the studies analyzed was the NLST (N=53,454), showing net health benefit from screening for lung cancer in a high-risk population of current and former smokers. Other smaller studies have not demonstrated the benefits of screening on the same scale as the NLST.
Clinical leaders and policy makers regard the benefits of LDCT screening for lung cancer with reservation owing to the potential harms of screening, uncertainty about the optimal screening interval, questions about the generalizability of results from a tightly controlled trial to real world settings and a range of other issues. Nonetheless, supportive recommendations and guidelines from numerous professional societies and patient advocacy groups have been issued, contributing to a growing momentum of screening services. (See Appendix for details.)
Discussion

Evidence for screening and value
The NLST provided sound evidence that screening high-risk individuals, defined as older (ages 55-74 years) and current or former heavy smokers (30 pack years or more), can save lives at an acceptable cost. Screening high-risk patients resulted in approximately 3 fewer deaths from lung cancer per 1000 patients screened, a 20% reduction in relative risk. However, even within this high risk group, there was significant variability in the value of screening: in younger participants, only 0.8 lives were saved for every 1000 screened vs.12 for the oldest smokers. In addition, since the post-surgical mortality rate in NLST subjects was significantly lower than the national average (1% vs. 3-4%), these outcomes may not be achieved in general practice.
Although the NLST cost effectiveness data are currently being analyzed and will be published in the future, preliminary results indicate an estimated cost per quality adjusted life year (QALY) saved as a result of screening high-risk patients to be $37,000, well within generally accepted boundaries for determining value. The evidence does not support screening in low-risk populations who are younger and have a shorter duration of cigarette exposure because the risks of radiation exposure outweigh reductions in morbidity and mortality.
Commercial and Public Coverage
Coverage policies among private insurers are trending toward paying for screening (see Appendix). Although a recent analysis by Milliman suggests that screening is a good value for commercial payers for people as young as 50 4 , insurers are staying close to the NLST guidelines in their medical policies. It remains to be seen if they will continue coverage for screening beyond the 3 annual CT scans studied in the NLST. Public insurers such as the VA, Medicare, and state Medicaid programs are proceeding cautiously, awaiting updated recommendations from the USPSTF. In 2013 the VA will launch a demonstration project at selected centers across the United States. Since public insurers tend to have a larger proportion of older smokers than private insurers, their policies for coverage will potentially have a greater impact on lives saved than private insurers.
Ongoing research
Although the NLST screened study participants annually for 3 years, the data do not yet exist to recommend the optimal screening interval or length of time to screen high-risk patients. Therefore, most professional guidelines are non-specific about these parameters and allow for a significant amount of clinical latitude. Similarly, questions about the importance of other risk factors (duration vs. intensity, second hand smoke exposure, age of exposure, etc.) and the psychological impact of screening on patients remain unanswered, although some additional data will be forthcoming from the NLST and other randomized trials.
Most likely, refinements to the current screening recommendations will not come from further large-scale trials but will depend on data modeling efforts and the collection and monitoring of data in real time. In addition to the VA pilot, other large health systems such as Kaiser and CMS --that have yet to embrace screening for lung cancer --present an opportunity to contribute to ongoing development of knowledge by creating registries and, where appropriate, adopting "coverage with evidence development" policies.
Community Stake
Advocacy groups, in addition to efforts to de-stigmatize lung cancer, have moved to legislate screening. They can be expected to continue to push for greater access to screening and the creation of a national screening program to reduce lung cancer mortality.
LDCT screening for lung cancer is a new revenue opportunity for community hospitals and imaging centers that are using direct-to-consumer campaigns, offering steeply discounted scans that bypass insurance medical policy altogether, effectively moving a screening agenda forward in the absence of new evidence. In our established system of free enterprise health care, lung cancer screening using LDCT presents an opportunity for many organizations and providers to simultaneously create new revenue while supporting a health care mission to save lives.
From study to practice
Screening for lung cancer is highly dependent on patient access to organizations that have the ability to carefully perform and accurately interpret LDCT and follow up on positive findings with comprehensive programs for their management. To date, there is no specialized certification (like the American College of Radiology's Mammography Accreditation Program) required for institutions performing LDCT for lung cancer screening to establish quality. While it is theoretically possible for screening to take place in community settings, follow up of positive findings are best referred to comprehensive programs for the necessary complex monitoring. However, until coordinated networks between screening centers and follow up programs are established, there is the risk that positive scans will be repeated (adding further cost and exposure risk) since many referral institutions will not read scans performed elsewhere.
The burden of implementing lung cancer screening falls most heavily in primary care. Not only will primary care practitioners be responsible for initiating lung cancer screening, explaining the pros and cons to patients and communicating results while coordinating follow up and referrals as needed, they will also be placed in the position of defending the criteria to low risk patients who nevertheless seek or, in some cases, demand screening. Unlike the radiologists, thoracic surgeons, and oncologists who can benefit financially from participating in screening programs, primary care providers are presented with additional responsibilities, some of which come without additional compensation.
Investing in Prevention
Surprisingly, given decades of research and public health programs, smoking cessation is not included in most lung cancer screening programs. Likewise, smoking cessation is not a requirement to enter most screening programs or to receive coverage for screening. It is also absent in proposed state and federal legislation mandating screening and demonstration projects.
5 While the population of smokers seeking screening may be motivated to quit smoking, smoking cessation parameters were not included in much of the research on screening for lung cancer. Yet given the increase in effective interventions to support tobacco 5 Current bills to legislate the creation of a national screening program (SB 752; HB 1394) are pending; similarly, bills to raise state-level funds and establish screening are pending (CT HB 923, MD HB 1167, GA HB 732) abstinence, public and private insurers have an opportunity at this early juncture in lung cancer screening to link coverage to participation in smoking cessation services in the future.
Opportunities Moving Forward
There is general agreement that screening is beneficial -both clinically and financially -when limited to high risk patients, defined as ages 55-74 with at least a 30 pack-year history of smoking who are current smokers or have smoked in the past 10 years. However, there continues to be controversy about broadening the screening to younger patients with a less intense smoking history, patients with co-morbidities, a past history of lung cancer or other medical factors. Treating physicians will continue to determine the value of screening in conjunction with their patients based on individual circumstances, while looking to future research to help clarify their decision-making.
Given the inherent complexities in lung cancer screening, a multi-faceted approach of best practices and innovative use of resources is needed. During both large group and break-out sessions at the symposium, suggestions from participants were elicited with the goals of clarifying the value of population screening and optimizing its benefits in practice.
Opportunities for quality screening and follow up can be attained by
1.1. Developing strategies for primary care practitioners to manage the complex and timeconsuming communication demands of screening. Examples of strategies include the use of group appointments for explanation of the risks and benefits to patients, webbased tools for the provider and the patient, the development of shared decision-making models, and the development of new team roles to insure coordinated communication. 1.2. Establishing quality standards for centers that perform LDCT screening for lung cancer.
Approaches might include linking scanning facilities to Centers of Excellence or following the model of mammography center credentialing. 1.3. Referring the management of positive findings on LDCT to comprehensive screening programs and mandating these referrals for coverage. Comprehensive screening programs should include a multidisciplinary approach in their design, elements such as risk assessment, smoking cessation, systems for tracking and follow-up, participation in registries, and integrated communication protocols and tools. Given the limited access to these programs, use of telemedicine approaches to extend care to rural and other underserved areas should be investigated as methods to increase capacity.
Further research is necessary to resolve screening uncertainties, including:
2.1. Quantifying the degree of over-diagnosis and developing tools for effectively communicating the risk for over-diagnosis to patients 2.2. Assessing the psychological harms of screening and labeling, such as patient and family anxiety, factors contributing to declining quality of life, effect of screening on work and relationships, etc, 2.3. Monitoring the real-world 60-day mortality following surgery for possible lung cancers identified by CT screening. 2.4. Modeling efforts to investigate the optimal time to initiate and stop screening, the optimal screening interval, the effect of a higher operative mortality on net benefits, and to incorporate the long term effects of increased radiation exposure on patient. 2.5. Additional cost analyses comparing LDCT Screening for Lung Cancer to other cancer screening programs.
Development of real-time learning systems, including:
3.1. Creating demonstration projects and registries to answer outstanding research questions. 3.2. Utilizing incentives and networks that encourage ongoing data collection through "coverage with evidence development"
Conclusion
While the NLST provides the most compelling evidence to date supporting LDCT in high-risk populations, screening recommendations may --and should --change as further evidence becomes available. In the not too distant future, large European trials will conclude, results from modeling studies will be published, and evidence regarding the true risks and benefits may be gleaned from observational studies built on registries. Additionally, other tests (such as immunobiomarker detection) may become available that will determine with greater precision those who will benefit from LDCT screening. The ongoing challenge is to keep evidence, practice and policy in sync so no area proceeds without check from the other. The complex process of translating evidence into practice and policy needs to also be informed by the translation of practice into actionable evidence and policy.
Given the rapid movement toward acceptance and coverage of LDCT screening for lung cancer in the U.S., evidence that contradicts the NLST will pose challenges to burgeoning screening programs. Considering the retraction of other cancer screening tests once promoted as beneficial -and the uproar from vested interests as well as justifiably confused consumers -it will be important to frame the current state of LDCT screening as provisional and subject to change.
